In the context of clinical trials, AAV6-μDys has been subjected to a phase I/II trial in DMD patients, in which, according to interim results, therapeutic levels of μDys, 81% dystrophin-positive fibers, and improvement in the North Star Ambulatory Assessment (NSAA) score were seen in all patients [238]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.